TORONTO, ON, March 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced that it has received a decision of the Nasdaq Hearings Panel (the "Panel") advising the Company that effective at the open of business on March 10, 2023, the Company's common shares will be delisted from The Nasdaq Stock Market ("Nasdaq"). On December 30, 2021, Nasdaq Listing Qualifications staff ("Staff") issued the Company a deficiency notice citing its failure to comply with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June

Toronto, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company's board of directors and audit committee, the Company no longer complies with Nasdaq's audit committee requirement set forth in Nasdaq Rule 5605. Senior Leadership Changes Following the announcement of February 8, 2023, the Company has decided to layoff certain members of the Company's senior leadership team. Each of these individuals remain available to a

TORONTO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today provided an update on the previously announced review and evaluation of strategic alternatives. As previously disclosed on November 30, 2022, Titan's Board of Directors determined that it was in the best interests of the Company and its stakeholders to undertake a review and evaluation of strategic alternatives and engaged Raymond James as the Company's financial advisor. At the direction of the Board, Titan's financial advisor and members of Titan's leadership team conducted a comprehensive outreach to over 40 potential counterparties, engaged in a number of management p

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the unveiling of its next generation technology and participation in meetings to support the strategic review process announced on November 30, 2022 alongside the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12 in San Francisco, CA. A video highlighting the company's latest innovation in robotic-assisted surgery is available on the company's website www.titanmedicalinc.com. Cary G. Vance, Titan's President and

TORONTO, ON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that the United States Patent and Trademark Office (USPTO) recently issued patent No. 11,504,191, titled "Graphical User Interface for a Robotic Surgical System." The patent, directed at enhancing the surgeon user experience, generally covers a graphical user interface (GUI) overlay of a surgical workspace to track instrument movement. "The granting of this patent is a result of our strategic plan to independently build and p

TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that in view of the commencement of the strategic review process announced on November 30, 2022, the special meeting of its shareholders scheduled for January 12, 2023 will be suspended and, if appropriate and necessary, rescheduled to a future date. If rescheduled to a future date, the business of the meeting may include, to the extent required by corporate or securities law and as determined by the Board of Directors of the company, the approval of a potential transaction should one result from the stra

TORONTO, ON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will implement certain cost-cutting measures with a view to preserving capital to support the strategic review process announced on November 30, 2022 while allowing the company to continue working on the investigational device exemption (IDE) filing with the U.S. Food and Drug Administration (FDA). As part of this plan, the company's U.S. subsidiary will be temporarily furloughing approximately 40 employees at its Chapel Hill, North Carolina facility effective immediately. "While t

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD) ("Titan" or the "Company"), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that its Board of Directors (or the "Board"), in consultation with its financial and legal advisors, has determined that it is in the best interest of the Company and its stakeholders to undertake a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value. As part of the process, the Board will consider a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congress on minimally invasive gynecologic surgery (MIGS) being held December 1-4, 2022 in Aurora, Colorado. "Participation at the American Association of Gynecologic Laparoscopy Global Congress aligns with Titan's mission of improving outcomes for patients, hospitals and surgeons in our initial pursuit of gynaecological surgical indications. Titan's technology maximizes patient outcomes by minimizing incisions, and

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and nine months ended September 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2). As previously shared, Nasdaq granted the company with an extension to regain compliance

Oppenheimer initiated coverage of Titan Medical with a rating of Outperform and set a new price target of $4.00

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and nine months ended September 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2). As previously shared, Nasdaq granted the company with an extension to regain compliance

TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and six months ended June 30, 2022. "I am thrilled to lead Titan Medical as President and CEO and have been committed to the company's mission to improve surgical outcomes as a director of the company since September 2020. We continue to make progress on impacting the future of minimally invasive robotic surgery and the operating room ecosystem. Our technical partnerships, our relationships with surg

Manufacturing Team and Capabilities Continue to Expand Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. "The entire team is focused on driving performance and progress supporting our IDE application submission milestone. We are also starting to prepare for the forthcoming commercialization of the Enos single-access RAS platform for gynecological surgery, our initial target indication for use," stated Paul Cataford, Interim President, CEO and Board Chair. "We are

Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery today announced that the company plans to issue its third quarter 2021 financial results prior to market opening on Thursday, November 11, 2021. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include David McNally, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. A link to the live audio webcast will be made available on the "Investor Relations" section of the Company's w

Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include David McNally, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. A link to the live audio webcast will be made available on the "Investor Relations" section of the Company's website, www.titanmedicali

Paul Cataford Appointed Chairman of the Board Heather Knight Appointed as Independent Director Cathy Steiner Nominated for Election as Independent Director Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three months ended March 31, 2021. During the first quarter of 2021 the company raised proceeds of $34.5 million from two equity financings and $10 million from the exercise of warrants issued to investors in previous offerings. Titan also announces changes to its board of directors appointing Paul Cataford as Chairman of the Board and He

TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the company's Vice President, Market and Corporate Development. Mr. Heinz will be responsible for developing and executing on strategic business plans to expand and accelerate Titan's Enos™ robotic single access surgical system's portfolio cadence. He will also lead existing partnerships and look to supplement those to maximize Titan's reach and the utilization of the Enos system. Mr. Hei

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been appointed as the company's President and CEO effective July 1, 2022. Mr. Vance will succeed Paul Cataford, Titan's chair of the board of directors, who has served as Interim President and CEO since December 2021. Mr. Vance previously served as President and CEO at Xcath Incorporated, a privately held neurovascular robotics company, and held similar positions at Optiscan Biomedical, and Myoscience. He a

TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company's Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of management's nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 54,760,905 of the 111,202,690 common shares outstanding, or 49.24%, were voted at the meeting. The results of the vote were reported to the meeting

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the appointment of Bill Fahey as Vice President, Manufacturing and Operations. In this new role, Mr. Fahey will be a key member of the senior leadership team and be responsible for both in-house and contract manufacturing relationships. He will also be working closely with Titan's product development and the quality and regulatory affairs teams as the company completes its Investigational Device Exemption (IDE) application and, fo

Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, announced that President and Chief Executive Officer David McNally has stepped down as President and CEO, and resigned from the Board of Directors effective today. Paul Cataford, Chair of the Board, has been appointed Interim President and CEO and Anthony J. Giovinazzo will assume the role of Lead Independent Director of the Board. The Board intends to commence a search process in early 2022 to identify a permanent CEO. Mr. Cataford has several years of medical device product development, regulatory affairs

Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs. "We are delighted that Tammy has joined Titan Medical's leadership team as we advance our Enos™ robotic single access surgery system toward human clinical studies," said David McNally, President and Chief Executive Officer. "Her proven track record in developing and implementing clinical and regulatory strategies, obtaining medical device regulatory clearances and successfully managing FDA inspections will be invaluable asset

Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Stephen Lemieux as the Chief Financial Officer of the Company. Mr. Lemieux has more than 18 years of experience working in Nasdaq and TSX listed companies primarily focused in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at over $400 million. Previously, Mr. Lemieux served as Chief Financial Officer and Secretary of NeuPath Health Inc. (TSXV:NPTH). Mr. Lemieux is a Chartered Professional Accountan

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the voting results from the company’s Annual and Special Meeting of its Shareholders held on Wednesday, June 9, 2021. All of management’s nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 56,098,112 of the 109,527,690 common shares outstanding, or 51.22%, were voted at the meeting. The results of the vote were reported to the meeting by Computershare, which acted as scrutineer

Kristen Galfetti Appointed as Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President, Finance Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Kristen Galfetti, MBA, as its Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President Finance. Ms. Galfetti will be located in Boston and Mr. Huang will be located in Toronto. "It is a pleasure to welcome both Kristen and Chien to Titan Medical. As the Titan team continues to grow and advan

Gainers Ocean Biomedical, Inc. (NASDAQ:OCEA) shares climbed 62.3% to $7.61 after the company shared detailed research data on anti-tumor pathway discoveries and their potential for treatment of non-small cell lung cancer, metastatic melanoma, and glioblastoma by Scientific Co-founder, Dr. Jack A. Elias, MD. Toro Corp. (NASDAQ:TORO) shares climbed 53.2% to $5.90. Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 36% to $2.21. EF Hutton initiated coverage on Unicycive Therapeutics with a Buy rating and announced a price target of $5. Holley Inc. (NYSE:HLLY) surged 32% to $2.6099 following Q4 results. Intuitive Machines, Inc. (NASDAQ:LUNR) rose 30.3% to $13.37 Solo Brands, Inc. (NYSE:D

Gainers Arbe Robotics Ltd. (NASDAQ:ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. Ambrx Biopharma Inc. (NYSE:AMAM) surged 59% to $5.17. Ambrx Biopharma recently announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients. Harbor Custom Development, Inc. (NASDAQ:HCDI) shares jumped 50.3% to $0.5260 after the company said it has contracted to sell mills Crossing townhomes for $14.25 million. Mobilicom Limited (NASDAQ:MOB) shares gained 37.4% to $2.1307 after the company announced it has entered a strategic partnership wi

Gainers TravelCenters of America Inc. (NASDAQ:TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash. NexImmune, Inc. (NASDAQ:NEXI) rose 62% to $0.6640 after the company announced data showing AIM ACT T cells enhance the response to bispecific T cell engager therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Ambrx Biopharma Inc. (NASDAQ:AMAM) climbed 52% to $2.7510 after the company reported initial data from its ongoing Phase 1 Apex-01 trial of ARX517 in prostate cancer patients, demonstrating prostate-specific antigen decrease of over 50% from baseline in 3 of 3 patients receiving 2.

Gainers Sera Prognostics, Inc. (NASDAQ:SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares climbed 63.4% to $0.7684 after the company requested the withdrawal of a registration statement, saying it has determined not to pursue the sale of securities at this time. Tenon Medical, Inc. (NASDAQ:TNON) rose 36.4% to $1.3513 after dropping 10% on Tuesday. Tenon Medical, during November, posted a Q3 loss of $0.28 per share. Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares rose 34.6% to $0.8771 after dropping 26% on Tuesday. Vallon Pharmaceuticals and GRI Bio recently announced they entered

Gainers Amesite Inc. (NASDAQ:AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users. Boxlight Corporation (NASDAQ:BOXL) gained 39% to $0.55. Boxlight authorized repurchase program of up to $15 million in shares of Class A common stock. Blue Water Vaccines, Inc. (NASDAQ:BWV) shares rose 30.8% to $1.5299. Blue Water Vaccines recently appointed Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Iris Energy Limited (NASDAQ:IREN) gained 32% to $2.8199. Iris Energy said it is increasing its self-mining capacity from 2.0 E

Titan Medical Inc. (the “Company” or “Titan”) (NASDAQ:TMDI, TSX:TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company’s board of directors and audit committee, the Company no longer complies with Nasdaq’s audit committee requirement set forth in Nasdaq Rule 5605.

  On Monday, 42 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Fisker (NYSE:FSR). The smallest company on a market cap basis to set a new 52-week low was Tivic Health Systems (NASDAQ:TIVC). Genius Brands Intl (NASDAQ:GNUS) was the biggest loser, trading down 724.9% to reach its 52-week low. Celularity (NASDAQ:CELU)'s stock bounced back the most, actually rising 0.03% after reaching its new 52-week low. Here is a list of stocks that set new 52-week lows on Monday: Fisker (NYSE:FSR) shares hit a yearly low of $6.40. The stock was down 4.46% on the session. Hanesbrands (NYSE:HBI) shares se

  On Wednesday, 20 companies achieved new lows for the year. 52-Week Low Highlights: Jack Henry & Associates (NASDAQ:JKHY) was the largest firm by market cap to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Edible Garden (NASDAQ:EDBL). Titan Medical (NASDAQ:TMDI)'s stock dropped the most, trading down 70.69% to reach a new 52-week low. TIM (NYSE:TIMB) was the biggest winner of the bunch, with shares actually trading up 0.19% after it rebounded from its new 52-week low. On Wednesday, the following stocks hit new 52-week lows: Jack Henry & Associates (NASDAQ:JKHY) shares set a new 52-week low of $164.00. The stock traded down 9.0%. TIM (NY